Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.
Nasdaq

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
Nasdaq

Rapport To Advance Phase 3 Program Of RAP-219 In Focal Onset Seizures In Q2

(RTTNews) - Rapport Therapeutics, Inc. (RAPP) said the U.S. FDA has cleared the company to advance RAP-219 into registrational trials, allowing accelerated initiation of its Phase 3 program in focal ...
Benzinga.com

Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year

Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro. On ...
Mena FN

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2A Follow-Up Period Results Demonstrating Sustained Seizure Reduction At The 2026 American Academy Of Neurology ...

BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the“Company”), a clinical-stage biotechnology company dedicated to the discovery and ...
Yahoo Finance

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...